Accessibility helpSkip to navigationSkip to contentSkip to footer

Cookies on FT Sites

We use cookies for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.

Accept & continue
Manage cookies
  • Sign In
  • Subscribe
Open side navigation menuOpen search bar
Financial Times
SubscribeSign InmyFT
  • Home
  • World
    Sections
    • World Home
    • Global Economy
    • UK
    • US
    • China
    • Africa
    • Asia Pacific
    • Emerging Markets
    • Europe
    • War in Ukraine
    • Americas
    • Middle East & North Africa
    • Australia & NZ
    Most Read
    • Japan’s latest alcohol advice: please drink more
    • Fed officials signal restrictive rates may be needed ‘for some time’
    • Covid can cause brain disorders two years after infection, study shows
    • Taiwan tensions force multinationals to rethink China risk
    • Top US health official admits ‘dramatic mistakes’ in tackling Covid
  • US
    Sections
    • US Home
    • US Economy
    • US Companies
    • US Politics & Policy
    Most Read
    • Companies
      Sections
      • Companies Home
      • Energy
      • Financials
      • Health
      • Industrials
      • Media
      • Professional Services
      • Retail & Consumer
      • Tech Sector
      • Telecoms
      • Transport
      Most Read
      • Mark Wahlberg-backed gym chain F45 goes from ab crunches to credit crunch
      • Average pay for PwC’s UK partners tops £1mn for first time
      • Jim Ratcliffe declares interest in buying Manchester United
      • Germany’s Uniper on the ‘brink of insolvency’ after €12bn loss
      • Toyota and Foxconn hit as drought leads to record low Yangtze River level
    • Tech
    • Markets
      Sections
      • Markets Home
      • Alphaville
      • Markets Data
      • Capital Markets
      • Commodities
      • Currencies
      • Equities
      • Fund Management
      • Trading
      • Moral Money
      • ETF Hub
      • Cryptofinance
      Most Read
      • University student makes $110mn trading meme stock favourite Bed Bath & Beyond
      • Taiwan tensions force multinationals to rethink China risk
      • City of London regulators to face shake-up under Liz Truss
      • ‘Shock the market’: Wall Street’s original ‘Dr Doom’ tells Fed to toughen up
      • Quant funds support market rally by ramping up bets on US stocks
    • Climate
    • Opinion
      Sections
      • Opinion Home
      • Columnists
      • The FT View
      • The Big Read
      • Lex
      • Obituaries
      • Letters
      Most Read
      • The truth that set Liz Cheney free
      • It’s time for Europe to ask Norway to cut the price of gas
      • China’s chip breakthrough poses strategic dilemma
      • Anshu Jain, banker, 1963—2022
      • Successful leaders don’t worry about party unity
    • Work & Careers
      Sections
      • Work & Careers Home
      • Business School Rankings
      • Business Education
      • Entrepreneurship
      • Recruitment
      • Business Books
      • Business Travel
      Most Read
      • Business Book of the Year 2022 — the longlist
      • Michelle O’Neill: ‘What I won’t allow is the unravelling of the Good Friday Agreement’
      • FT business books: what to read this month
    • Life & Arts
      Sections
      • Life & Arts Home
      • Arts
      • Books
      • Food & Drink
      • FT Magazine
      • House & Home
      • Style
      • Travel
      • FT Globetrotter
      Most Read
      • The village wedding caught in the Taliban’s battle for Kabul
      • When your childhood hero turns into a Trumpist
      • Food writer Juana Pepa on her favourite things
      • Chef Aktar Islam’s top places to eat in Toronto
      • A taste of Sicily: caponata, pasta with sardines and apricot ricotta cake — recipes
    • HTSI
    MenuSearch
    • Home
    • World
    • US
    • Companies
    • Tech
    • Markets
    • Climate
    • Opinion
    • Work & Careers
    • Life & Arts
    • HTSI
    Financial Times
    SubscribeSign In

    Your guide to a disrupted world

    Start a 4-week trial

    Hannah Kuchler

    Global Pharmaceuticals Correspondent
    Hannah Kuchler reports on the pharmaceutical industry and the Covid-19 pandemic. She previously covered US pharma and biotech in New York and the technology industry in Silicon Valley.
    Email Hannah Kuchler @hannahkuchler  on Twitter (link opens in a new browser window)
    Email Hannah Kuchler @hannahkuchler  on Twitter (link opens in a new browser window)

    Add to myFT Digest

    Add this topic to your myFT Digest for news straight to your inbox

    • Tuesday, 16 August, 2022
      AstraZeneca PLC
      AstraZeneca sues former executive over move to rival GSK

      Pharma group alleges breach of non-compete agreement to delay start date of departing business development official

    • Monday, 15 August, 2022
      Covid-19 vaccines
      UK becomes first country to approve Omicron-specific Covid booster

      Moderna’s two-strain shot will target both the original strain and BA.1 in step with European regulators

    • Sunday, 14 August, 2022
      The Big Read
      How science is getting closer to a world without animal testing

      New technology involving miniature human organs built in a lab is a step towards better treatments and ending a contentious practice

    • Friday, 12 August, 2022
      NHS England
      NHS England to increase beds and call handlers as winter crisis looms

      Push to create equivalent of 7,000 extra beds and boost recruitment follows testing summer for health service

    • Thursday, 11 August, 2022
      Pharmaceuticals sector
      Pharma groups lose £30bn of value on heartburn drug lawsuit worries

      Companies face thousands of pending personal injury cases linking Zantac to cancer

    • Monday, 8 August, 2022
      Covid-19 vaccines
      BioNTech and Pfizer to begin vaccine clinical trial for new Covid variants

      German biotech aims for ‘prolonged and broad protection’ as sales and earnings miss expectations

    • Saturday, 30 July, 2022
      AstraZeneca PLC
      AstraZeneca to double number of countries where US biotech arm sells rare disease drugs

      Anglo-Swedish pharmaceutical group wants to capitalise on its $39bn acquisition of Alexion

    • Friday, 29 July, 2022
      AstraZeneca PLC
      AstraZeneca raises forecasts after strong Covid and cancer drug sales

      Chief executive says revenue rise will allow drugmaker to boost investment in R&D

    • Wednesday, 27 July, 2022
      GSK PLC
      GSK raises profit guidance after strong sales of shingles vaccine

      Quarterly figures beat expectations as pharma group strengthens pipeline of new drugs

    • Thursday, 21 July, 2022
      Joe Biden
      Joe Biden has contracted Covid, White House says

      US president has ‘very mild symptoms’ and is taking Pfizer antiviral pill

    • Wednesday, 20 July, 2022
      Biotech
      Cambridge biotech Abcam to abandon London listing for Nasdaq

      Further blow to UK stock market comes despite government’s efforts to promote life sciences

    • Saturday, 16 July, 2022
      GSK PLC
      GSK split will help deal with ‘perennial underperformance’, says chief

      Emma Walmsley believes listing of consumer health business will strengthen pharma division

    • Thursday, 14 July, 2022
      FT Magazine
      A new ‘miracle’ weight-loss drug really works — raising huge questions

      Novo Nordisk’s Wegovy uses a hormone to regulate hunger. It’s wildly effective, but is it misguided?

    • Thursday, 14 July, 2022
      Health
      UK lags behind EU in authorising new medicines after Brexit

      Experts attribute shortfall to small size of British market now it is regulated separately and complexity of dealing with NHS

    • Wednesday, 13 July, 2022
      Pfizer Inc
      Why Pfizer’s ‘living with Covid’ pill is not a miracle drug

      Antiviral treatment Paxlovid is being widely prescribed despite questions about its effectiveness

    • Sunday, 10 July, 2022
      Covid-19 vaccines
      More than 1bn Covid vaccine jabs wasted in pandemic, data analysis suggests

      Shots unused due to factors including hesitancy, improper storage and donations delivered close to expiry dates

    • Thursday, 7 July, 2022
      Pharmaceuticals sector
      Merck in talks over $40bn deal for cancer biotech SeaGen

      US group attracted by approved drugs as it prepares to lose patent protection of Keytruda

    • Wednesday, 6 July, 2022
      GSK PLC
      GSK investor support for spin-off vindicates rejection of Unilever bid, says chief

      Vote to separate consumer healthcare paves way for London’s largest stock market listing in a decade

    • Wednesday, 6 July, 2022
      FT Financial Literacy and Inclusion Campaign
      Employers urged to help workers navigate stresses of cost of living crisis

      Mounting money worries spark calls for companies to support workers’ financial wellbeing

    • Tuesday, 5 July, 2022
      CureVac GmbH
      CureVac sues BioNTech over mRNA patents

      Pharma group seeks compensation from Covid vaccine maker for alleged IP infringements

    • Friday, 1 July, 2022
      Covid-19 vaccines
      Oxford BioMedica extends Covid vaccine deal with AstraZeneca

      New three-year contract in place if UK drugmaker continues to manufacture the jab

    • Wednesday, 29 June, 2022
      Q&ACoronavirus pandemic
      How worried should we be about new Covid variants?

      FT science editor Clive Cookson and global pharma correspondent Hannah Kuchler answered your questions about rising Omicron infections and vaccine efficiency

    • Monday, 27 June, 2022
      Croda International PLC
      US government to invest up to $75mn in new Croda factory

      Washington seeks to expand domestic production of crucial component of mRNA vaccines

    • Saturday, 25 June, 2022
      Covid-19 vaccines
      BioNTech/Pfizer say Omicron-targeting boosters elicit strong immune response

      New vaccine candidates significantly outperform existing Covid jabs at targeting the most prevalent strain

    • Friday, 24 June, 2022
      Covid-19 vaccines
      Sanofi-GSK Covid vaccine found effective against Omicron

      Pharma companies are hoping to catch up with rivals as they report promising trial results for jab

    Previous page You are on page 1 Next page

    Useful links

    Support

    View Site TipsHelp CentreContact UsAbout UsAccessibilitymyFT TourCareers

    Legal & Privacy

    Terms & ConditionsPrivacy PolicyCookiesCopyrightSlavery Statement & Policies

    Services

    Share News Tips SecurelyIndividual SubscriptionsGroup SubscriptionsRepublishingExecutive Job SearchAdvertise with the FTFollow the FT on TwitterFT ChannelsSecondary Schools

    Tools

    PortfolioToday's Newspaper (ePaper)Alerts HubBusiness School RankingsEnterprise ToolsNews feedNewslettersCurrency Converter

    Community & Events

    FT CommunityFT LiveFT ForumsFT Board DirectorBoard Director Programme

    More from the FT Group

    Markets data delayed by at least 15 minutes. © THE FINANCIAL TIMES LTD 2022. FT and ‘Financial Times’ are trademarks of The Financial Times Ltd.
    The Financial Times and its journalism are subject to a self-regulation regime under the FT Editorial Code of Practice.
    Financial Times

    International Edition

    Subscribe for full access
    • Switch to UK Edition
    • Top sections
    • Home
    • World
      • Global Economy
      • UK
      • US
      • China
      • Africa
      • Asia Pacific
      • Emerging Markets
      • Europe
      • War in Ukraine
      • Americas
      • Middle East & North Africa
      • Australia & NZ
    • US
      • US Economy
      • US Companies
      • US Politics & Policy
    • Companies
      • Energy
      • Financials
      • Health
      • Industrials
      • Media
      • Professional Services
      • Retail & Consumer
      • Tech Sector
      • Telecoms
      • Transport
    • Tech
    • Markets
      • Alphaville
      • Markets Data
      • Capital Markets
      • Commodities
      • Currencies
      • Equities
      • Fund Management
      • Trading
      • Moral Money
      • ETF Hub
      • Cryptofinance
    • Climate
    • Opinion
      • Columnists
      • The FT View
      • The Big Read
      • Lex
      • Obituaries
      • Letters
    • Work & Careers
      • Business School Rankings
      • Business Education
      • Entrepreneurship
      • Recruitment
      • Business Books
      • Business Travel
    • Life & Arts
      • Arts
      • Books
      • Food & Drink
      • FT Magazine
      • House & Home
      • Style
      • Travel
      • FT Globetrotter
    • Personal Finance
      • Property & Mortgages
      • Investments
      • Pensions
      • Tax
      • Banking & Savings
      • Advice & Comment
      • Next Act
    • HTSI
    • Special Reports
    • FT recommends
    • Lex
    • Alphaville
    • Lunch with the FT
    • FT Globetrotter
    • #techAsia
    • Moral Money
    • FTfm
    • Newsletters
    • Video
    • Podcasts
    • News feed
    • FT Community
      • FT Live
      • FT Forums
      • Board Director Programme
    • myFT
    • Portfolio
    • Today's Newspaper (ePaper)
    • Crossword
    • Our Apps
    • Help Centre
    • Subscribe
    • Sign In